Cytokinetics, Incorporated Receives FDA Approval for MYQORZO™ (aficamten)

Cytokinetics, Incorporated announced on December 19, 2025, that the U.S. Food and Drug Administration (FDA) has approved MYQORZO™ (aficamten) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The drug, available in 5 mg, 10 mg, 15 mg, and 20 mg tablets, is designed to improve functional capacity and symptoms in patients with oHCM. MYQORZO™ functions as an allosteric and reversible inhibitor of cardiac myosin motor activity, which in turn reduces cardiac contractility and left ventricular outflow tract (LVOT) obstruction in individuals with oHCM.